OMEROS CORP Operating Leases, Income Statement, Sublease Revenue
OMEROS CORP (OMER) reported Operating Leases, Income Statement, Sublease Revenue of $848.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-01.
Discontinued › Income Statement › Other Income
us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue · last filed 2019-03-01
- OMEROS CORP operating leases, income statement, sublease revenue for fiscal 2018 was $848.00K, a 4.29% decline from fiscal 2017.
- OMEROS CORP operating leases, income statement, sublease revenue for fiscal 2017 was $886.00K, a 20.22% increase from fiscal 2016.
- OMEROS CORP operating leases, income statement, sublease revenue for fiscal 2016 was $737.00K.
- OMEROS CORP operating leases, income statement, sublease revenue for fiscal 2014 was $568.00K, a 3.27% increase from fiscal 2013.
| Period end | Operating Leases, Income Statement, Sublease Revenue 12 month | Operating Leases, Income Statement, Sublease Revenue 12 month as first filed |
|---|---|---|
| 2018-12-31 | $848.00K 10-K · filed 2019-03-01 | |
| 2017-12-31 | $886.00K 10-K · filed 2019-03-01 | |
| 2016-12-31 | $737.00K 10-K · filed 2019-03-01 | |
| 2014-12-31 | $568.00K 10-K · filed 2015-03-16 | |
| 2013-12-31 | $550.00K 10-K · filed 2015-03-16 | $550.00M 10-K · filed 2014-03-13 |
| 2012-12-31 | $635.00K 10-K · filed 2015-03-16 | |
| 2011-12-31 | $693.00M 10-K · filed 2014-03-13 | $693.00K 10-K · filed 2013-03-18 |
| 2010-12-31 | $793.00K 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |